Opening book details…
Can I read SOX9 as an emerging target for anticancer drugs and a prognostic biomarker for cancer drug resistance on EtoBox?
SOX9 as an emerging target for anticancer drugs and a prognostic biomarker for cancer drug resistance by Surya Kant Tripathi; Rajeev Kumar Sahoo; Bijesh Kumar Biswal is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.
What is SOX9 as an emerging target for anticancer drugs and a prognostic biomarker for cancer drug resistance about?
The dysregulated expression of the transcription factor (TF) Sry-related HMG box 9 (SOX9) has been extensively correlated with various biological effects, including the initiation and progression of cancer. Differential expression of SOX9 has been positively correlated with cancer cell growth, invasion, migration, metastasis, and therapy resistance. Studies showed that expression of SOX9 affects the expression of various miRNAs and vice versa, resulting in the development of cancer drug resistance. However, modulating the expression of SOX9 reverses drug resistance by modulating the expression of miRNAs. Therefore, in this review, we summarize current research focusing on SOX9 as a cancer therapeutic target and a prognostic biomarker of cancer drug resistance.
Who reads SOX9 as an emerging target for anticancer drugs and a prognostic biomarker for cancer drug resistance?
It is typically read by researchers, students, and practitioners in Biochemistry, Genetics and Molecular Biology.
- Author
- Surya Kant Tripathi; Rajeev Kumar Sahoo; Bijesh Kumar Biswal
- Publisher
- Elsevier BV
- Published
- 2022
- Language
- EN
- Field
- Biochemistry, Genetics and Molecular Biology (Life Sciences)
More by Surya Kant Tripathi; Rajeev Kumar Sahoo; Bijesh Kumar Biswal
Browse all works by Surya Kant Tripathi; Rajeev Kumar Sahoo; Bijesh Kumar Biswal